Journal article
Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol
Alicia Calderone, Wendy Stevens, David Prior, Harshal Nandurkar, Eli Gabbay, Susanna M Proudman, Trevor Williams, David Celermajer, Joanne Sahhar, Peter KK Wong, Vivek Thakkar, Nathan Dwyer, Jeremy Wrobel, Weng Chin, Danny Liew, Margaret Staples, Rachelle Buchbinder, Mandana Nikpour
BMJ Open | BMJ PUBLISHING GROUP | Published : 2016
Grants
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Awarded by NHMRC
Funding Acknowledgements
This study is financially supported by a peer-reviewed 5-year Project Grant (APP1062638) from the National Health and Medical Research Council of Australia (NHMRC). MN holds an NHMRC Research Fellowship (APP1071735). RB holds an NHMRC Senior Research Fellowship (APP1082138). The study drug and matching placebo are being supplied at no cost by Bristol-Myers Squibb Pty. Bristol-Myers Squibb were permitted to review the manuscript and make suggestions, but the final decision on content was exclusively retained by the authors. MN has received research support from Actelion, GlaxoSmithKline and Pfizer.